Evidence map›Paper›PMID 38927544›Full record

ArticleBiomedicines2024

The Role of Macrophage Inhibitory Factor in TAA-Induced Liver Fibrosis in Mice: Modulatory Effects of Betaine.

Tatjana Radosavljevic, Dusan Vukicevic, Jasmina Djuretić, Kristina Gopcevic, Milica Labudovic Borovic, Sanja Stankovic, Janko Samardzic, Milica Radosavljevic, Danijela Vucevic, Vladimir Jakovljevic

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tatjana RadosavljevicInstitute of Pathophysiology "Ljubodrag Buba Mihailović", Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-1701-3313
Dusan VukicevicUniklinik Mannheim, Theodor-Kutyer-Ufer 1-3, 68167 Mannheim, Germany.
Jasmina DjuretićDepartment of Pathobiology, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-8457-4962
Kristina GopcevicInstitute of Chemistry in Medicine "Prof. Dr. Petar Matavulj", Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Milica Labudovic BorovicInstitute of Histology and Embryology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Sanja StankovicCentre for Medical Biochemistry, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0003-0890-535X
Janko SamardzicInstitute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-8464-4924
Milica RadosavljevicInstitute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0009-0004-4591-7143
Danijela VucevicInstitute of Pathophysiology "Ljubodrag Buba Mihailović", Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Vladimir JakovljevicDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.

Funding

Faculty of Medical Sciences, University of Kragujevac (JP 27/20) and the Ministry of Science, Technical Development, and Innovation of the Republic of Serbia 451-03-47/2023-01/200111; 451-03-66/2024-03/200110; 451-03-65/2024-03/ 200161; 451-03-66/2024-03/ 200161.
6 · The paper itself

Abstract

Macrophage inhibitory factor (MIF) is a multipotent cytokine, involved in the inflammatory response to infections or injuries. This study investigates the role of MIF in liver fibrosis and the modulating effect of betaine on MIF in thioacetamide (TAA)-induced liver fibrosis. The wild-type and knockout MIF-/- C57BL/6 mice were divided into the following groups: control; Bet group, which received betaine; MIF-/-; MIF-/-+Bet; TAA group, which received TAA; TAA+Bet; MIF-/-+TAA; and MIF-/-+TAA+Bet group. After eight weeks of treatment, liver tissue was collected for further analysis. The results revealed that TAA-treated MIF-deficient mice had elevated levels of hepatic TGF-β1 and PDGF-BB, as well as MMP-2, MMP-9, and TIMP-1 compared to TAA-treated wild-type mice. However, the administration of betaine to TAA-treated MIF-deficient mice reduced hepatic TGF-β1 and PDGF-BB levels and also the relative activities of MMP-2, MMP-9 and TIMP-1, albeit less effectively than in TAA-treated mice without MIF deficiency. Furthermore, the antifibrogenic effect of MIF was demonstrated by an increase in MMP2/TIMP1 and MMP9/TIMP1 ratios. The changes in the hepatic levels of fibrogenic factors were confirmed by a histological examination of liver tissue. Overall, the dual nature of MIF highlights its involvement in the progression of liver fibrosis. Its prooxidant and proinflammatory effects may exacerbate tissue damage and inflammation initially, but its antifibrogenic activity suggests a potential protective role against fibrosis development. The study showed that betaine modulates the antifibrogenic effects of MIF in TAA-induced liver fibrosis, by decreasing TGF-β1, PDGF-BB, MMP-2, MMP-9, TIMP-1, and the deposition of ECM (Coll1 and Coll3) in the liver.

Indexed as

betaineliver fibrosismacrophage migration inhibitory factormicethioacetamide

Identifiers

PMID38927544
PMCPMC11201963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.